Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Ivermectin to Prevent COVID-19 Hospitalisation in Adults Over 50
2020-005015-40Phase 3Terminated
- Sponsor
- Chemo
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Ivermectin with Placebo (2 arms). Primary endpoint: Hospitalisation due to SARS-CoV-2. Started Mar 2021; status: terminated.
02
Drugs
ivermectin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005015-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005015-40.